Cargando…
Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine
The CVnCoV (CureVac) mRNA vaccine for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) was recently evaluated in a phase 2b/3 efficacy trial in humans(1). CV2CoV is a second-generation mRNA vaccine containing non-modified nucleosides but with optimized non-coding regions and enhanced ant...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8770133/ https://www.ncbi.nlm.nih.gov/pubmed/34794169 http://dx.doi.org/10.1038/s41586-021-04231-6 |
_version_ | 1784635299954950144 |
---|---|
author | Gebre, Makda S. Rauch, Susanne Roth, Nicole Yu, Jingyou Chandrashekar, Abishek Mercado, Noe B. He, Xuan Liu, Jinyan McMahan, Katherine Martinot, Amanda Martinez, David R. Giffin, Victoria Hope, David Patel, Shivani Sellers, Daniel Sanborn, Owen Barrett, Julia Liu, Xiaowen Cole, Andrew C. Pessaint, Laurent Valentin, Daniel Flinchbaugh, Zack Yalley-Ogunro, Jake Muench, Jeanne Brown, Renita Cook, Anthony Teow, Elyse Andersen, Hanne Lewis, Mark G. Boon, Adrianus C. M. Baric, Ralph S. Mueller, Stefan O. Petsch, Benjamin Barouch, Dan H. |
author_facet | Gebre, Makda S. Rauch, Susanne Roth, Nicole Yu, Jingyou Chandrashekar, Abishek Mercado, Noe B. He, Xuan Liu, Jinyan McMahan, Katherine Martinot, Amanda Martinez, David R. Giffin, Victoria Hope, David Patel, Shivani Sellers, Daniel Sanborn, Owen Barrett, Julia Liu, Xiaowen Cole, Andrew C. Pessaint, Laurent Valentin, Daniel Flinchbaugh, Zack Yalley-Ogunro, Jake Muench, Jeanne Brown, Renita Cook, Anthony Teow, Elyse Andersen, Hanne Lewis, Mark G. Boon, Adrianus C. M. Baric, Ralph S. Mueller, Stefan O. Petsch, Benjamin Barouch, Dan H. |
author_sort | Gebre, Makda S. |
collection | PubMed |
description | The CVnCoV (CureVac) mRNA vaccine for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) was recently evaluated in a phase 2b/3 efficacy trial in humans(1). CV2CoV is a second-generation mRNA vaccine containing non-modified nucleosides but with optimized non-coding regions and enhanced antigen expression. Here we report the results of a head-to-head comparison of the immunogenicity and protective efficacy of CVnCoV and CV2CoV in non-human primates. We immunized 18 cynomolgus macaques with two doses of 12 μg lipid nanoparticle-formulated CVnCoV or CV2CoV or with sham (n = 6 per group). Compared with CVnCoV, CV2CoV induced substantially higher titres of binding and neutralizing antibodies, memory B cell responses and T cell responses as well as more potent neutralizing antibody responses against SARS-CoV-2 variants, including the Delta variant. Moreover, CV2CoV was found to be comparably immunogenic to the BNT162b2 (Pfizer) vaccine in macaques. Although CVnCoV provided partial protection against SARS-CoV-2 challenge, CV2CoV afforded more robust protection with markedly lower viral loads in the upper and lower respiratory tracts. Binding and neutralizing antibody titres were correlated with protective efficacy. These data demonstrate that optimization of non-coding regions can greatly improve the immunogenicity and protective efficacy of a non-modified mRNA SARS-CoV-2 vaccine in non-human primates. |
format | Online Article Text |
id | pubmed-8770133 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-87701332022-02-04 Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine Gebre, Makda S. Rauch, Susanne Roth, Nicole Yu, Jingyou Chandrashekar, Abishek Mercado, Noe B. He, Xuan Liu, Jinyan McMahan, Katherine Martinot, Amanda Martinez, David R. Giffin, Victoria Hope, David Patel, Shivani Sellers, Daniel Sanborn, Owen Barrett, Julia Liu, Xiaowen Cole, Andrew C. Pessaint, Laurent Valentin, Daniel Flinchbaugh, Zack Yalley-Ogunro, Jake Muench, Jeanne Brown, Renita Cook, Anthony Teow, Elyse Andersen, Hanne Lewis, Mark G. Boon, Adrianus C. M. Baric, Ralph S. Mueller, Stefan O. Petsch, Benjamin Barouch, Dan H. Nature Article The CVnCoV (CureVac) mRNA vaccine for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) was recently evaluated in a phase 2b/3 efficacy trial in humans(1). CV2CoV is a second-generation mRNA vaccine containing non-modified nucleosides but with optimized non-coding regions and enhanced antigen expression. Here we report the results of a head-to-head comparison of the immunogenicity and protective efficacy of CVnCoV and CV2CoV in non-human primates. We immunized 18 cynomolgus macaques with two doses of 12 μg lipid nanoparticle-formulated CVnCoV or CV2CoV or with sham (n = 6 per group). Compared with CVnCoV, CV2CoV induced substantially higher titres of binding and neutralizing antibodies, memory B cell responses and T cell responses as well as more potent neutralizing antibody responses against SARS-CoV-2 variants, including the Delta variant. Moreover, CV2CoV was found to be comparably immunogenic to the BNT162b2 (Pfizer) vaccine in macaques. Although CVnCoV provided partial protection against SARS-CoV-2 challenge, CV2CoV afforded more robust protection with markedly lower viral loads in the upper and lower respiratory tracts. Binding and neutralizing antibody titres were correlated with protective efficacy. These data demonstrate that optimization of non-coding regions can greatly improve the immunogenicity and protective efficacy of a non-modified mRNA SARS-CoV-2 vaccine in non-human primates. Nature Publishing Group UK 2021-11-18 2022 /pmc/articles/PMC8770133/ /pubmed/34794169 http://dx.doi.org/10.1038/s41586-021-04231-6 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Gebre, Makda S. Rauch, Susanne Roth, Nicole Yu, Jingyou Chandrashekar, Abishek Mercado, Noe B. He, Xuan Liu, Jinyan McMahan, Katherine Martinot, Amanda Martinez, David R. Giffin, Victoria Hope, David Patel, Shivani Sellers, Daniel Sanborn, Owen Barrett, Julia Liu, Xiaowen Cole, Andrew C. Pessaint, Laurent Valentin, Daniel Flinchbaugh, Zack Yalley-Ogunro, Jake Muench, Jeanne Brown, Renita Cook, Anthony Teow, Elyse Andersen, Hanne Lewis, Mark G. Boon, Adrianus C. M. Baric, Ralph S. Mueller, Stefan O. Petsch, Benjamin Barouch, Dan H. Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine |
title | Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine |
title_full | Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine |
title_fullStr | Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine |
title_full_unstemmed | Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine |
title_short | Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine |
title_sort | optimization of non-coding regions for a non-modified mrna covid-19 vaccine |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8770133/ https://www.ncbi.nlm.nih.gov/pubmed/34794169 http://dx.doi.org/10.1038/s41586-021-04231-6 |
work_keys_str_mv | AT gebremakdas optimizationofnoncodingregionsforanonmodifiedmrnacovid19vaccine AT rauchsusanne optimizationofnoncodingregionsforanonmodifiedmrnacovid19vaccine AT rothnicole optimizationofnoncodingregionsforanonmodifiedmrnacovid19vaccine AT yujingyou optimizationofnoncodingregionsforanonmodifiedmrnacovid19vaccine AT chandrashekarabishek optimizationofnoncodingregionsforanonmodifiedmrnacovid19vaccine AT mercadonoeb optimizationofnoncodingregionsforanonmodifiedmrnacovid19vaccine AT hexuan optimizationofnoncodingregionsforanonmodifiedmrnacovid19vaccine AT liujinyan optimizationofnoncodingregionsforanonmodifiedmrnacovid19vaccine AT mcmahankatherine optimizationofnoncodingregionsforanonmodifiedmrnacovid19vaccine AT martinotamanda optimizationofnoncodingregionsforanonmodifiedmrnacovid19vaccine AT martinezdavidr optimizationofnoncodingregionsforanonmodifiedmrnacovid19vaccine AT giffinvictoria optimizationofnoncodingregionsforanonmodifiedmrnacovid19vaccine AT hopedavid optimizationofnoncodingregionsforanonmodifiedmrnacovid19vaccine AT patelshivani optimizationofnoncodingregionsforanonmodifiedmrnacovid19vaccine AT sellersdaniel optimizationofnoncodingregionsforanonmodifiedmrnacovid19vaccine AT sanbornowen optimizationofnoncodingregionsforanonmodifiedmrnacovid19vaccine AT barrettjulia optimizationofnoncodingregionsforanonmodifiedmrnacovid19vaccine AT liuxiaowen optimizationofnoncodingregionsforanonmodifiedmrnacovid19vaccine AT coleandrewc optimizationofnoncodingregionsforanonmodifiedmrnacovid19vaccine AT pessaintlaurent optimizationofnoncodingregionsforanonmodifiedmrnacovid19vaccine AT valentindaniel optimizationofnoncodingregionsforanonmodifiedmrnacovid19vaccine AT flinchbaughzack optimizationofnoncodingregionsforanonmodifiedmrnacovid19vaccine AT yalleyogunrojake optimizationofnoncodingregionsforanonmodifiedmrnacovid19vaccine AT muenchjeanne optimizationofnoncodingregionsforanonmodifiedmrnacovid19vaccine AT brownrenita optimizationofnoncodingregionsforanonmodifiedmrnacovid19vaccine AT cookanthony optimizationofnoncodingregionsforanonmodifiedmrnacovid19vaccine AT teowelyse optimizationofnoncodingregionsforanonmodifiedmrnacovid19vaccine AT andersenhanne optimizationofnoncodingregionsforanonmodifiedmrnacovid19vaccine AT lewismarkg optimizationofnoncodingregionsforanonmodifiedmrnacovid19vaccine AT boonadrianuscm optimizationofnoncodingregionsforanonmodifiedmrnacovid19vaccine AT baricralphs optimizationofnoncodingregionsforanonmodifiedmrnacovid19vaccine AT muellerstefano optimizationofnoncodingregionsforanonmodifiedmrnacovid19vaccine AT petschbenjamin optimizationofnoncodingregionsforanonmodifiedmrnacovid19vaccine AT barouchdanh optimizationofnoncodingregionsforanonmodifiedmrnacovid19vaccine |